RIC3抗体—艾普蒂

+ +

•  

   

     Gel: 10%SDS-PAGE, Lysate: 50 μg, Lane 1-3: A549 cells, human liver cancer tissue, Hela cells, Primary antibody: P07706(STXBP2 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 40 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human lung cancer tissue using P07706(STXBP2 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P07706(STXBP2 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The RIC3 (Resistance to Inhibitors of Cholinesterase 3) antibody is a tool used to study the RIC3 protein, a chaperone critical for the assembly and functional maturation of nicotinic acetylcholine receptors (nAChRs). These receptors play key roles in cholinergic signaling, impacting processes like neurotransmitter release, synaptic plasticity, and neuromuscular function. RIC3 is particularly essential for the proper folding and surface expression of specific nAChR subtypes, including α7 receptors, which are implicated in cognitive functions and neuropsychiatric disorders. Dysregulation of RIC3 has been linked to neurological conditions such as Alzheimer’s disease, epilepsy, and schizophrenia.

Antibodies targeting RIC3 enable researchers to investigate its expression patterns, interaction partners, and regulatory mechanisms. They are widely used in techniques like Western blotting, immunohistochemistry, and co-immunoprecipitation to explore RIC3's role in neuronal development, receptor trafficking, and disease pathology. Studies using RIC3 antibodies have revealed tissue-specific expression profiles, with high levels observed in the brain, spinal cord, and endocrine tissues. Additionally, these antibodies aid in understanding how RIC3 mutations or polymorphisms affect receptor function and contribute to disease susceptibility. As a research tool, RIC3 antibodies support both basic neuroscience and therapeutic development targeting nAChR-related disorders.